Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Daratumumab (Dara) is an anti-cd38 monoclonal antibody (mAb) approved for the treatment of multiple myeloma, and binding to CD38 on red blood cells (rbc) causes false-positive agglutination in indirect antiglobulin tests (IATs). And Dara can interferes with IATs in nearly 100% of patients.